Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older

• Status: Completed
• Trial end date: 2012-03-01

Summary

Observational study at the request of the Belgian Institut National d'Assurance Maladie-Invalidité / Rijksinstituut voor Ziekte-en Invaliditeits Verzekering INAMI/RIZIV:

• type of patient treated with VIMPAT®

• VIMPAT® dose

• Effect of VIMPAT® on evolution of seizure control

• Persistence rate at 6 months in terms of treatment duration

• Discontinuation rate

• Description of any changes in other epilepsy therapies

• Safety and tolerability

Details

• Lead Sponsor: UCB Pharma
• Treatments: Lacosamide